Author

D. Bohan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

W. Maury· 2 shared A. Addetia· 1 shared A. Ceschi· 1 shared A. Franzetti-Pellanda· 1 shared A. Rajesh· 1 shared B. Gao· 1 shared B. Guarino· 1 shared B. Whitener· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

W. Maury

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Epitranscriptomic N6-methyladenosine profile of SARS-CoV-2-infected human lung epithelial cells

S. Phillips, S. Khadka, D. Bohan, C. E. Espada, W. Maury, L. Wu

This study examines how m6A modification of host cell RNAs changes during SARS-CoV-2 infection in human lung epithelial cells and identifies associated biological pathways and regulators.

bioRxiv · Aug 1, 2022Microbiology

Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19

D. Bohan, H. Van Ert, N. Ruggio, K. J. Rogers, M. Baddredine, J. A. A. Briseno, R. A. Rojas Chavez, B. Gao, T. Stokowy, E. Christakou, D. Micklem, G. Gausdal, H. Haim, J. Minna, J. B. Lorens, W. Maury

This study identifies PS receptors, including AXL, as facilitators of SARS-CoV-2 infection by enhancing virus entry into human lung cells, suggesting AXL as a therapeutic target for COVID-19.

bioRxiv · Jun 15, 2021Microbiology